阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

已收盘 01-09 16:00:00 EST

94.65

+0.64

+0.68%

盘后94.86

+0.21+0.22%

19:56 EST

最高95.94	最低94.54	成交量607.75万
今开95.24	昨收94.01	日振幅1.49%
总市值2,936亿	流通市值2,923亿	总股本31.01亿
成交额5.78亿	换手率0.20%	流通股本30.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":94.65,"timestamp":1767992400000,"preClose":94.01,"halted":0,"volume":6077496,"hourTrading":{"tag":"盘后","latestPrice":94.86,"preClose":94.65,"latestTime":"19:56 EST","volume":60807,"amount":5755556.7382,"timestamp":1768006582786},"delay":0,"floatShares":3088302520,"shares":3101451738,"eps":3.009339,"marketStatus":"已收盘","change":0.64,"latestTime":"01-09 16:00:00 EST","open":95.24,"high":95.935,"low":94.535,"amount":578297957.144064,"amplitude":0.014892,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.009339,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":5,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":94.01,"dividendRate":0.016535,"preHourTrading":{"tag":"盘前","latestPrice":95.28,"preClose":94.01,"latestTime":"09:29 EST","volume":38636,"amount":3677637.9775199997,"timestamp":1767968970044},"postHourTrading":{"tag":"盘后","latestPrice":94.86,"preClose":94.65,"latestTime":"19:56 EST","volume":60807,"amount":5755556.7382,"timestamp":1768006582786},"volumeRatio":1.084156,"impliedVol":0.3077,"impliedVolPercentile":0.8486},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2602002463","title":"汇宇制药（688553）披露与阿斯利康达成临床研究合作，1月9日股价上涨6.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602002463","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602002463?lang=zh_cn&edition=full","pubTime":"2026-01-10 08:55","pubTimestamp":1768006559,"startTime":"0","endTime":"0","summary":"公司近日发布公告称，其全资子公司汇宇海玥与阿斯利康签署《临床试验合作协议》，就自主研发的I类创新药HYP-6589片与阿斯利康的奥希替尼联合治疗特定类型非小细胞肺癌的临床研究展开合作。本次合作不构成重大资产重组，无需提交公司董事会或股东会审议，预计不会对公司财务状况和经营成果产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260110/31931449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4007","BK4568","LU0109394709.USD","LU1829250122.USD","AZN","BK4585","LU0320765992.SGD","LU2236285917.USD","BK4588","688553","LU0889565916.HKD","LU2456880835.USD","BK0239","LU2417539215.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2602323004","title":"汇宇制药(688553.SH)子公司与阿斯利康达成临床研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602323004","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602323004?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:27","pubTimestamp":1767947265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，汇宇制药 发布公告，公司全资子公司汇宇海玥自主研发的I类创新药HYP-6589片是一种高选择性SOS1小分子抑制剂。近日公司全资子公司汇宇海玥与阿斯利康签署了《临床试验合作协议》，就HYP-6589片与奥希替尼临床联合用药研究展开合作。公司与阿斯利康达成临床研究合作，合作双方共同探索公司自主研发的化学药I类创新药HYP-6589片与阿斯利康奥希替尼联合治疗特定类型非小细胞肺癌的疗法。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","688553","LU2456880835.USD","LU0320765992.SGD","LU2236285917.USD","BK0239","BK4585","LU0889565916.HKD","AZN","BK4568","LU1829250122.USD","LU2462157665.USD","LU2417539215.USD","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2602006340","title":"千亿美元“专利悬崖”逼近！美股制药巨头瞄准收购新药，中小盘生物科技股迎来“超级溢价”投资盛宴？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602006340","media":"智通财经","labels":["merge"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602006340?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:00","pubTimestamp":1767945631,"startTime":"0","endTime":"0","summary":"而多种因素共同促成了生物科技并购的爆发式增长。一些全球最畅销的药物正面临在关键地区失去专利保护的风险，这被业内称为“专利悬崖”。据计算，到2032年，畅销品牌专利保护期的丧失将造成至少1739亿美元的年销售额损失。生物科技板块近几年经历繁荣、衰退，然后又是繁荣新冠疫情期间，生物科技行业迅速成为投资者的热门之选。Loren表示，一系列利好数据也推高了生物科技股的估值。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390856.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股制药巨头瞄准收购新药，中小盘生物科技股迎来“超级溢价”投资盛宴？","news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVS","PFE","MRK","AZN","BMY","GSK","LLY","NVO"],"gpt_icon":1},{"id":"2601361281","title":"阿斯利康任命内部人士为美国生物制药部门主管","url":"https://stock-news.laohu8.com/highlight/detail?id=2601361281","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601361281?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:54","pubTimestamp":1767876850,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","LU2462157665.USD","BK4568","BK4585","AZN","LU0320765992.SGD","LU2417539215.USD","BK4007","BK4588","LU0889565916.HKD"],"gpt_icon":0},{"id":"2601967618","title":"高盛：1月5日剔除阿斯利康股票确信买入名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2601967618","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601967618?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:34","pubTimestamp":1767612854,"startTime":"0","endTime":"0","summary":"1月5日丨高盛将阿斯利康股票从其欧洲确信买入名单中剔除。本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105193844a49ed3b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260105193844a49ed3b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0320765992.SGD","BK4568","LU2417539215.USD","BK4588","LU0889565916.HKD","LU2456880835.USD","LU0109394709.USD","LU1829250122.USD","LU2462157665.USD","BK4585","AZN","LU2236285917.USD"],"gpt_icon":0},{"id":"2601006991","title":"高盛将阿斯利康股票从其欧洲确信买入名单中剔除。","url":"https://stock-news.laohu8.com/highlight/detail?id=2601006991","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601006991?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:44","pubTimestamp":1767599088,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1868837300.USD","LU0251131958.USD","LU0106831901.USD","IE0034235188.USD","LU2236285917.USD","LU2265009873.SGD","LU1868837136.USD","BK4504","IE00B19Z3B42.SGD","LU1894683264.USD","LU2237443978.SGD","LU2471134796.USD","IE0002270589.USD","BK4585","LU0345770308.USD","IE00BFXG1179.USD","LU2237443465.HKD","LU0320765992.SGD","LU1868836914.USD","BK4552","AZN","IE00B19Z3581.USD","BK4007","LU1791807156.HKD","LU0251142724.SGD","LU0345770993.USD","LU0061475181.USD","LU2750360641.GBP","LU2462157665.USD","IE0004091025.USD","LU0109394709.USD","LU2237443622.USD","IE00BSNM7G36.USD","BK4588","LU0048573561.USD","LU2750360997.AUD","LU2471134952.CNY","BK4516","BK4550","BK4568","LU1829250122.USD","LU1868836757.USD","LU2471134523.USD","LU0889565916.HKD","LU2237443895.HKD","LU2237443549.SGD","LU2237438978.USD","BK4127","BK4533","IE0004086264.USD"],"gpt_icon":0},{"id":"2594225778","title":"和誉医药首个自研创新药获批；Agios首创疗法再获FDA批准；阿斯利康自免“迷你双抗”在华申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2594225778","media":"药财社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594225778?lang=zh_cn&edition=full","pubTime":"2025-12-25 19:01","pubTimestamp":1766660515,"startTime":"0","endTime":"0","summary":"据悉，该药物是和誉医药旗下首个获批上市的自研创新药产品，也是中国首个自主研发的腱鞘巨细胞瘤系统性治疗药物。2Agios首创疗法再获FDA批准Agios Pharmaceuticals近日宣布，美国FDA已批准口服丙酮酸激酶激活剂Aqvesme用于治疗α型或β型地中海贫血成年患者。根据新闻稿，mitapivat为首款同时获FDA批准用于治疗非输血依赖型和输血依赖型α或β地中海贫血的药物。3阿斯利康自免“迷你双抗”在华申报上市12月24日，CDE网站显示，阿斯利康的戈鲁利单抗在华申报上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225201123a6ce9548&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","BK4007","BK4588","LU0109394709.USD","LU0320765992.SGD","BK4585","LU2417539215.USD","LU2456880835.USD","LU2236285917.USD","LU2462157665.USD","LU0889565916.HKD","BK4568","LU1829250122.USD"],"gpt_icon":0},{"id":"2594257739","title":"阿斯利康罕见病新药万诺维获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2594257739","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594257739?lang=zh_cn&edition=full","pubTime":"2025-12-25 17:19","pubTimestamp":1766654340,"startTime":"0","endTime":"0","summary":"12月25日，界面新闻从阿斯利康处获悉，其与Ionis公司联合开发的万诺维®（英文商品名：Wainua®，通用名：依普隆特生钠注射液）在中国正式获批，该药物用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病（ATTRv-PN）患者。作为中国首个且目前唯一获批用于ATTRv-PN治疗的基因沉默剂，万诺维®的获批为ATTRv-PN患者提供了新的治疗选择，填补了国内在这一领域的治疗空白，有望显著改善患者生活质量，对推动国内罕见病治疗发展具有重要意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225173529a6ce0eb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225173529a6ce0eb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","LU0109394709.USD","LU2456880835.USD","BK4585","AZN","BK4007","LU2462157665.USD","LU0889565916.HKD","LU2236285917.USD","BK4588","BK4568","LU1829250122.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2594572762","title":"超 70 亿美元引进！阿斯利康小核酸疗法国内获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2594572762","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594572762?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:44","pubTimestamp":1766652263,"startTime":"0","endTime":"0","summary":"12 月 25 日，NMPA 官网显示，阿斯利康的 Eplontersen注射液在国内获批上市。此前，Eplontersen已于 2023 年 12 月获美国 FDA 批准上市，用于治疗成人遗传性转甲状腺素蛋白介导的淀粉样变性多发性神经病。2025 年 3 月，该药在欧盟获批同适应症。2023 年 7 月，双方再次扩大合作，阿斯利康又获得了在拉丁美洲商业化 Eplontersen 的独家权利，此项合作总金额也超过 36 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172611a6ce05d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225172611a6ce05d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0109394709.USD","BK4588","LU0889565916.HKD","LU2417539215.USD","BK4007","LU2456880835.USD","LU1829250122.USD","LU0320765992.SGD","LU2462157665.USD","LU2236285917.USD","BK4585","AZN","BK4568"],"gpt_icon":0},{"id":"2594233412","title":"阿斯利康与第一三共ADC抗癌药在华获批第五项适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2594233412","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594233412?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:43","pubTimestamp":1766652224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0109394709.USD","BK4080","ADC","LU2417539215.USD","LU1829250122.USD","BK4585","LU2236285917.USD","LU2456880835.USD","BK4588","LU0889565916.HKD","AZN","LU2462157665.USD","BK4231","LU0320765992.SGD","BK4007","BK4568"],"gpt_icon":0},{"id":"2594025721","title":"阿斯利康“戈鲁利单抗”国内申报上市，自免双抗新药剑指全身型重症肌无力","url":"https://stock-news.laohu8.com/highlight/detail?id=2594025721","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594025721?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:33","pubTimestamp":1766644399,"startTime":"0","endTime":"0","summary":"12月24日，据CDE网站显示，阿斯利康的戈鲁利单抗在国内申报上市。根据临床试验进展，推测此次申报的适应症为全身型重症肌无力。全身型重症肌无力是一种罕见、慢性且严重影响生活的自身免疫性神经肌肉疾病，其特征是进行性肌力下降与虚弱。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225143342a6cd5c28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225143342a6cd5c28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","AZN","BK4007","LU0889565916.HKD","BK4585","LU2417539215.USD","LU2456880835.USD","LU0109394709.USD","LU2236285917.USD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","BK4568"],"gpt_icon":0},{"id":"2593479219","title":"加科思与阿斯利康合作开发KRAS抑制剂 交易总额突破20亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593479219","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593479219?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:10","pubTimestamp":1766574606,"startTime":"0","endTime":"0","summary":"本报讯（记者张敏）近日，港股上市公司加科思药业集团有限公司（以下简称“加科思”）发布的公告显示，非全资附属公司北京加科思新药研发有限公司（以下简称“北京加科思”）与AstraZenecaAB（以下简称“阿斯利康”）订立许可与合作协议（以下简称“许可及合作协议”），就开发及商业化泛KRAS抑制剂JAB-23E73展开合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600872266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4568","LU2236285917.USD","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","LU2417539215.USD","LU2456880835.USD","AZN","LU2462157665.USD","BK4588","LU0109394709.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2593421806","title":"阿斯利康(AZN.US)自免双抗“戈鲁利单抗”在华申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2593421806","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593421806?lang=zh_cn&edition=full","pubTime":"2025-12-24 13:52","pubTimestamp":1766555567,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月24日，CDE网站显示，阿斯利康的戈鲁利单抗在华申报上市。根据临床试验进展，推测此次申报的适应症为全身型重症肌无力。戈鲁利单抗是一种迷你双抗，只包含了靶向C5的抗体重链可变区和与白蛋白特异性结合的抗体片段。全身型重症肌无力是一种罕见、使人衰弱、慢性的自身免疫性神经肌肉疾病，会导致肌肉功能丧失和严重无力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"阿斯利康(AZN.US)自免双抗“戈鲁利单抗”在华申报上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","BK4588","LU0889565916.HKD","LU2417539215.USD","BK4007","LU2456880835.USD","LU1829250122.USD","LU0320765992.SGD","LU2462157665.USD","LU2236285917.USD","BK4585","AZN","BK4568"],"gpt_icon":0},{"id":"2593428103","title":"港股异动 | 加科思-B(01167)涨近5% 公司获阿斯利康近20亿美元BD大单 公司称首付比例均值偏上","url":"https://stock-news.laohu8.com/highlight/detail?id=2593428103","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593428103?lang=zh_cn&edition=full","pubTime":"2025-12-24 10:48","pubTimestamp":1766544525,"startTime":"0","endTime":"0","summary":"加科思将获得1亿美元的首付款，根据开发及商业化进度，还可获得最高19.15亿美元的里程碑付款，以及中国以外市场的净销售额特许权使用费。首付款占总金额比例为5%。在12月22日加科思召开的媒体沟通会上，加科思董事长兼首席执行官王印祥回应称，加科思此次BD交易是中国近几年来处于临床阶段的小分子抗肿瘤药中金额最大的对外授权。王印祥在沟通会上回应了首付款是否低于预期这一问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU0320765992.SGD","BK4588","BK4007","LU0109394709.USD","LU0889565916.HKD","LU2456880835.USD","01167","LU2236285917.USD","BK4585","BK4568","LU2417539215.USD","LU1829250122.USD","LU2462157665.USD","AZN","BK1574"],"gpt_icon":0},{"id":"2593433677","title":"阿斯利康肺癌试验药物组合未达到主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2593433677","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593433677?lang=zh_cn&edition=full","pubTime":"2025-12-22 22:12","pubTimestamp":1766412720,"startTime":"0","endTime":"0","summary":"阿斯利康表示，其试验性药物ceralasertib与已获批的癌症治疗药物Imfinzi的组合，在一项针对晚期肺癌的后期临床试验中未能达到主要目标。　　这家英国制药公司周一表示，研究结果显示，与局部晚期或转移性非小细胞肺癌患者的标准疗法相比，ceralasertib组合未能达到总体生存率这一主要目标。　　阿斯利康表示，ceralasertib和Imfinzi的组合总体上耐受性良好，没有出现新的安全性担忧。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-22/doc-inhcsvvf6086289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4588","LU2417539215.USD","AZN","LU1829250122.USD","LU2462157665.USD","LU0109394709.USD","BK4568","LU0889565916.HKD","LU2456880835.USD","LU0320765992.SGD","BK4007","LU2236285917.USD"],"gpt_icon":0},{"id":"2593448816","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593448816","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593448816?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:55","pubTimestamp":1766393727,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家开发和商业化权利。在中国市场，加科思将与阿斯利康共同开发和商业化该产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598339468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZN","BK4007","BK4588","LU0109394709.USD","LU0320765992.SGD","BK4585","LU2417539215.USD","LU2456880835.USD","LU2236285917.USD","LU2462157665.USD","LU0889565916.HKD","BK4568","LU1829250122.USD"],"gpt_icon":0},{"id":"2593171901","title":"阿斯利康入局，Pan-KRAS抑制剂技术路线之争开始逆转","url":"https://stock-news.laohu8.com/highlight/detail?id=2593171901","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593171901?lang=zh_cn&edition=full","pubTime":"2025-12-22 08:45","pubTimestamp":1766364328,"startTime":"0","endTime":"0","summary":"当阿斯利康以20亿美元接手加科思 Pan-KRAS抑制剂项目的全球开发后，这场竞赛的本质已经发生变化。更重要的是，对阿斯利康来说，一个安全性更好的分子，更有可能在未来KRAS抑制剂联合治疗版图中占据优势。对阿斯利康来说，Pan-KRAS 的终极目标并不仅仅是在某个小人群中证明“能用”，而是成为联用时代的底座。相比之下，加科思 Pan-KRAS抑制剂 采用的是更为传统、成熟的小分子路线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2456880835.USD","BK4568","01167","LU0109394709.USD","LU2417539215.USD","BK4588","LU0889565916.HKD","LU2236285917.USD","BK4585","BK4007","LU2462157665.USD","BK1574","BK1161","AZN","LU1829250122.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2593124204","title":"加科思-B(01167)附属与阿斯利康订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73","url":"https://stock-news.laohu8.com/highlight/detail?id=2593124204","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593124204?lang=zh_cn&edition=full","pubTime":"2025-12-21 19:58","pubTimestamp":1766318290,"startTime":"0","endTime":"0","summary":"加科思-B(01167)公布，该集团的非全资附属公司北京加科思新药研发有限公司与AstraZeneca \nAB(阿斯利康)已订立许可与合作协议，以开发及商业化泛KRAS抑制剂JAB-23E73。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_30.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_30.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0889565916.HKD","BK4568","LU2236285917.USD","LU0109394709.USD","AZN","BK4007","BK4588","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","01167","BK1161","LU1829250122.USD","BK1574","LU2417539215.USD","BK4585"],"gpt_icon":0},{"id":"2592139231","title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_cn&edition=full","pubTime":"2025-12-20 07:00","pubTimestamp":1766185200,"startTime":"0","endTime":"0","summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","LU0096364046.USD","IE00B2B36J28.USD","LU0234572021.USD","LU0265550359.USD","IE00BJJMRZ35.SGD","LU0980610538.SGD","GILD","SG9999002224.SGD","LU1670710661.SGD","IE00B4R5TH58.HKD","BK4534","LU0237698245.USD","LU1571399168.USD","LU1934455194.USD","LU1670710588.SGD","LU0006306889.USD","LU0211331839.USD","LU1032466523.USD","LU1061106388.HKD","BK4516","IE000M9KFDE8.USD","LU0208291251.USD","LU0965509010.AUD","BK4532","LU0225284248.USD","LU0321505439.SGD","SG9999014559.SGD","SG9999002232.USD","BK4581","LU0114720955.EUR","SG9999015358.SGD","BMY","SG9999001176.SGD","LU0965509101.SGD","LU0106261372.USD","BK4533","LU1430594728.SGD","LU1868837136.USD","LU1035773651.USD","ABBV","LU0122379950.USD","REGN","IE00BJT1NW94.SGD","04332","BK4585","LU1162221912.USD","IE00BFXG1179.USD","LU2023250843.SGD","IE00BFTCPJ56.SGD","LU0456855351.SGD","SG9999014542.SGD","LU1323610961.USD","LU0266013472.USD","LU0289739699.SGD","IE00BLSP4239.USD","BK4588","LU2242646821.SGD","LU2324357040.USD","LU0058720904.USD","LU1929549753.HKD","LU1941712264.USD","LU0238689110.USD","LU2133065610.SGD","LU1585245621.USD","IE00BN8TJ469.HKD","LU2242652126.USD","MRK","LU1989771016.USD","LU1934455277.USD","LU0477156953.USD","LU1868836914.USD","LU2112291526.USD","LU1066051811.HKD","LU0320765646.SGD","IE00B1BXHZ80.USD","LU1074936037.SGD","LU1116320737.USD","LU0861579265.USD","AMGN","LU1983299246.USD","GSK","LU1917777945.USD","SG9999014567.USD","LU0203345920.USD","LU1057294990.SGD","LU2360032135.SGD","BK4007","LU2468319806.SGD","SG9999013999.USD","IE00BBT3K403.USD","SG9999015341.SGD","LU1066051498.USD","LU1989772923.USD","LU0130102774.USD","LU0320765489.SGD","LU1974910355.USD","LU1261432733.SGD","LU0985320562.USD","LU0061475181.USD","LU0868494617.USD","LU0267386448.USD","LU1670711123.USD","IE0009355771.USD","LU0203347892.USD","LU1037948897.HKD","LU1868837300.USD","LU2125154778.USD","SGXZ57979304.SGD","LU2106854487.HKD","SG9999001176.USD","LU2125154935.USD","LU1023059063.AUD","IE00BLSP4452.SGD","LU1699723380.USD","LU0098860793.USD","LU1093756168.USD","SG9999001440.SGD","LU1868836591.USD","AZN","LU0306807586.USD","LU0225771236.USD","LU1868836757.USD","SG9999014575.USD","LU2089984988.USD","LU1066051225.USD","LU0965508806.USD","LU1718418525.SGD","LU1670711040.USD","LU0985481810.HKD","LU1989772840.SGD","LU2361044949.HKD","LU0965509283.SGD","LU1116320901.HKD","LU1934455863.HKD","LU0070302665.USD","LU0306806265.USD","LU1291159041.SGD","LU0265550946.USD","LU0321505868.SGD","JNJ","LU2023250504.SGD","LU2361044865.SGD","LU2461242641.AUD","LU1201861249.SGD","NVS","BK4559","IE00BSNM7G36.USD","LU1093756325.SGD","LU2361045086.USD","LU1037948541.HKD","LU1941712348.USD","LU0648001328.SGD","SNY","LU1069347547.HKD","LU1066053197.SGD","LU0882574055.USD","ROG","BK4550","LU0130517989.USD"],"gpt_icon":1},{"id":"2592199939","title":"阿斯利康甲磺酸奥希替尼片启动II期临床 适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2592199939","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592199939?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:03","pubTimestamp":1766138580,"startTime":"0","endTime":"0","summary":"本次试验目的是评估不适合或拒绝化疗的EGFRm阳性III期不可切除NSCLC患者在放疗前使用奥希替尼作为诱导治疗及在放疗后继续使用奥希替尼直至疾病进展的有效性。甲磺酸奥希替尼片为化学药物，适应症为不适合或拒绝化疗的EGFR常见突变阳性III期不可切除NSCLC患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219185751a6b6da17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0889565916.HKD","BK4568","BK4585","LU0320765992.SGD","LU2417539215.USD","LU2462157665.USD","LU1829250122.USD","LU0109394709.USD","AZN","BK4588","III","LU2236285917.USD","LU2456880835.USD","BK4134"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.0226},{"period":"1month","weight":0.0466},{"period":"3month","weight":0.1121},{"period":"6month","weight":0.3217},{"period":"1year","weight":0.412},{"period":"ytd","weight":0.0226}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.1057},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.00207},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}